NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Wuxi Pharma Tech
»03/03/2010 [Company watch]
WuXi PharmaTech Forms Pre-Clinical Collaboration With Janssen

WuXi PharmaTech (NYSE: WX) has struck a two-way pre-clinical services deal with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. WuXi PharmaTech will provide toxicology and other non-clinical services to Janssen, while Janssen will help WuXi attain GLP status in its new Suzhou toxicology lab.

 

WuXi PharmaTech (NYSE: WX) has struck a two-way pre-clinical services deal with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. WuXi PharmaTech will provide toxicology and other non-clinical services to Janssen, while Janssen will help WuXi attain GLP status in its new Suzhou toxicology lab.

Under the agreement, Janssen will provide training and other services, reimbursed by WuXi, to help WuXi establish GLP-level systems and technical capabilities in the Suzhou lab. The new Suzhou facility is the largest in China, with 314,000 square feet of space.

After construction was completed in late 2008, WuXi hired a management team with international experience and began training its staff of technicians to perform GLP services. At present, the facility is conducting non-GLP toxicology services, as well as client-sponsored GLP validation studies. WuXi PharmaTech expects to begin offering GLP toxicology studies by mid-2010.

As we reported last week, the facility has already been granted AAALAC accreditation, recognizing that the lab has instituted international standards of animal care.

Here is a list of WuXi’s facilities in China:

  • Shanghai Waigaoqiao Free Trade Zone – a 782,000-square-foot R&D center, and a 22,000-square-foot cGMP-quality formulation pilot plant;
  • Shanghai’s Jinshan area – a 293,000-square-foot cGMP-quality process development and manufacturing plant;
  • Tianjin – a 253,000-square-foot R&D center;
  • Suzhou’s Wuzhong district – a 314,000-square-foot toxicology center

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.